Accessed 24 November 2017
Compiled by Tin Geber for HIVOS. London, March 2018
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002514 March 1, 2018
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
1-13 December 2018 | Geneva, Switzerland UNAIDS Programme Coordinating Board Issue date: 23 November 2018
UNAIDS/PCB (43)/18.32
PLOS ONE | https://doi.org/10.1371/journal.pone.0196239 April 23, 2018
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
Evaluation Report
Evaluation Office
Programme Brief
Accessed: 21.08.2019
PLOS ONE | https://doi.org/10.1371/journal.pone.0196380 May 15, 2018
Training materials for healthcare workers
Topics in Antiviral Medicine Volume 25 Issue 2 May/June 2017
This document describes the key areas that national governments should consider for the introduction and scale-up of point-of-care (POC) diagnostics within national programmes, as new innovative POC technologies are being introduced into the market. The next steps taken to include these new innovati...ons within the broader context of national diagnostic networks of conventional laboratories could influence the achievement of the 2030 Fast Track targets for ending the AIDS epidemic.
POC diagnostics, when strategically introduced and integrated into national diagnostic networks, may help catalyse changes that improve the way diagnostics and clinical services are delivered. This document distils this understanding based on programmatic and market experiences of introducing POC diagnostics through catalytic investments in POC HIV technologies across numerous countries in sub-Saharan Africa.
more
1PEP GUIDELINES | 2019 EDITION. The prevalence of both HIV and Hepatitis B is high in South Africa therefore there is a significant risk of acquiring these infections following exposure to infected material. Studies suggest that post- exposure prophylaxis (PEP) with highly active antiretroviral trea...tment (HAART) is highly effective in preventing HIV infection if taken correctly for the full recommended duration of 28 days, and that prophylaxis with Hepatitis B immunoglobulin and vaccination may prevent Hepatitis B infection if given soon after exposure. This update of the Western Cape guidelines for management of potentially infectious exposures is based on current evidence and guidelines issued by the WHO, NDoH and the SA HIV Clinicians Society. The key aim is to promote successful completion of the recommended ART regimen in the 28 day period of therapy, as well as prevent infection with Hepatitis B
more